Vlaar, Alexander P. J ;
de Bruin, Sanne ;
Busch, Matthias...
Vlaar , A P J , de Bruin , S , Busch , M , Timmermans , S A M E G , van Zeggeren , I E , Koning , R , ter Horst , L , Bulle , E B , van Baarle , F E H P , van de Poll , M C G , Kemper , E M , van der Horst , I C C , Schultz , M J , Horn , J , Paulus , F , Bos , L D , Wiersinga , W J , Witzenrath , M , Rueckinger , S , Pilz , K , Brouwer , M C , Guo , R-F , Heunks , L , van Paassen , P , Riedemann , N C & van de Beek , D 2020 , ' Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO) : an exploratory, open-label, phase 2 randomised controlled trial ' , The Lancet Rheumatology , vol. 2 , no. 12 , pp. E764-E773 . https://doi.org/10.1016/s2665-9913(20)30341-6.
,
2020
